Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | USP5 | P45974 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.45 |
| ▸ | CCR3 | P51677 | 2/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14112396 | 0.99 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C19LRRK2L3MBTL3 | |
| SCHEMBL14112401 | 0.90 | OPRK1 (0.47) | CYP3A4CYP2D6CYP2C19SMN1; SMN2POLB | |
| SCHEMBL14112491 | 0.90 | CCR3 (0.46) | CYP3A4CYP2D6CYP2C19L3MBTL3L3MBTL1 | |
| SCHEMBL14112482 | 0.89 | THRA (0.51) | POLBCCR3CXCR3 | |
| SCHEMBL14112246 | 0.89 | POLB (0.45) | CYP3A4CYP2D6CYP2C19SMN1; SMN2POLB | |
| SCHEMBL14112400 | 0.89 | USP5 (0.49) | L3MBTL3L3MBTL1POLBUSP5CCR3 | |
| SCHEMBL14112399 | 0.89 | USP5 (0.49) | L3MBTL3L3MBTL1POLBUSP5CXCR3 | |
| SCHEMBL14112492 | 0.89 | CCR3 (0.46) | CYP3A4CYP2D6CYP2C19POLBCCR3 | |
| SCHEMBL14112447 | 0.89 | POLB (0.56) | POLBCCR3 | |
| SCHEMBL14112404 | 0.89 | CCR3 (0.46) | POLBCCR3CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CYP3A4 916/4885CYP2D6 519/4885CYP2C19 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.